Network pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19
Melissa Alegría‐Arcos(University of the Americas), David Ramírez(University of Concepción), Germán Combariza(Universidad Externado de Colombia), Carmen Gil(Instituto de Salud Carlos III), Janneth González(Pontificia Universidad Javeriana), Felipe Sepúlveda(Universidad Católica de la Santísima Concepción), Tábata Barbosa(Pontificia Universidad Javeriana), Ana Martı́nez(Consejo Superior de Investigaciones Científicas)
Cited by 22
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293